Adrenocortical Carcinoma Market: Steady Growth Driven by Emerging Pipeline Innovation by 2036

DelveInsight's "Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of Adrenocortical Carcinoma (ACC), historical and forecasted epidemiology as well as the ACC market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To Know in detail about the Adrenocortical Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adrenocortical Carcinoma Market Forecast https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Highlights from Adrenocortical Carcinoma Market Report:
• The ACC market size was valued at approximately USD 23 million in the leading markets (the United States, EU4, the United Kingdom, and Japan) in 2025, and is anticipated to grow at a significant CAGR of ~15% during the forecast period (2026-2036).
• The United States accounted for the largest ACC market size among the 7MM, valued at approximately USD 10 million in 2025, and is projected to grow at a significant CAGR through 2036.
• The United States also accounted for the highest incident cases of ACC, representing approximately 30% of total cases in the 7MM in 2025.
• In July 2025, Cytovation announced that the WHO-INN Expert Committee approved getacatetide as the International Nonproprietary Name (INN) for its investigational agent CY-101.
• In April 2025, Cytovation raised USD 6 million from existing investors to advance CY-101 into a multi-national Phase II clinical trial in ACC patients, with first clinical readouts expected in 2026.
• In January 2025, Cytovation, Cancer Research UK, and the Norwegian Cancer Society signed a collaboration agreement to bring CY-101 into a multi-national Phase II clinical trial for ACC patients.
• Mitotane (LYSODREN), marketed by Esteve, remains the only US FDA-approved drug specifically indicated for ACC, used both as adjuvant therapy after surgery and for advanced, inoperable disease.
• In the 7MM, Stage IV disease accounts for the highest share of ACC cases at approximately 35%, followed by Stage II and Stage III, with Stage I representing the lowest share at approximately 10%.
• ACC incidence is markedly higher in females (~60%) compared to males, reflecting a notable gender disparity in disease occurrence.
• ACC incidence rises with age, with the highest proportion observed among individuals aged over 60 years, closely followed by the 40-60 years age group.
• Key Adrenocortical Carcinoma Companies: Esteve, Daiichi Sankyo, Cytovation, Orphagen Pharmaceuticals, and others
• Key Adrenocortical Carcinoma Therapies: Mitotane (LYSODREN), DS9051b/DS-9051, CY-101/Getacatetide, OR-449, and others
• The ACC pipeline remains in relatively early development, with investigational agents spanning immunomodulatory, targeted molecular, and steroidogenesis-pathway approaches; however, several academically-driven programs, including EO2401 in combination with nivolumab, have been discontinued, underscoring a significant unmet need in the space.

Adrenocortical Carcinoma Overview
Adrenocortical Carcinoma (ACC) is a rare but aggressive malignancy arising from the adrenal cortex, with an etiology that remains largely elusive, though genetic mutations and hereditary syndromes are implicated. ACC may be functioning (hormone-secreting) or non-functioning, with functioning tumors often producing excess cortisol, androgens, or aldosterone that lead to clinical syndromes such as Cushing's syndrome or virilization. The oncocytic variant is the most common subtype, accounting for approximately 10% of adrenal cortical tumors, followed by the exceedingly rare myxoid and sarcomatoid variants. The ENSAT staging system, ranging from Stage I to Stage IV, is widely used to classify ACC and guide treatment decisions. Due to its aggressive nature, ACC is frequently diagnosed at an advanced stage, contributing to poor prognosis and high recurrence rates.

Get a Free sample for the Adrenocortical Carcinoma Market Report: https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Adrenocortical Carcinoma Epidemiology Insights
The epidemiology segment for ACC offers information on the past and present patient populations affected by the condition and predicts future trends across seven significant countries. It aids in understanding the factors driving current and anticipated trends by examining various studies and insights from key opinion leaders. "Findings from the ACC epidemiological analysis indicate that in the 7MM, Stage IV cases represent the highest share at approximately 35% of the total, likely stemming from delayed diagnosis, aggressive disease behavior, and limited screening methods. The disease shows a notable gender disparity, with incidence approximately 60% higher in females than males, and incidence rises progressively with age, peaking among individuals older than 60 years."

Adrenocortical Carcinoma Epidemiology Segmentation: The ACC market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Incident Cases of Adrenocortical Carcinoma
• Stage-specific Incident Cases of Adrenocortical Carcinoma
• Gender-specific Incident Cases of Adrenocortical Carcinoma
• Age-specific Incident Cases of Adrenocortical Carcinoma

Download the report to understand which factors are driving Adrenocortical Carcinoma epidemiology trends @ Adrenocortical Carcinoma Epidemiology Forecast https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Adrenocortical Carcinoma Therapies and Key Companies
• Mitotane (LYSODREN): Esteve
• DS9051b/DS-9051: Daiichi Sankyo
• CY-101/Getacatetide: Cytovation
• OR-449: Orphagen Pharmaceuticals

Emerging Adrenocortical Carcinoma Drugs Uptake: This section on ACC concentrates on the adoption rate of newly introduced or anticipated ACC medications within the market between 2026 and 2036. The evaluation includes the acceptance of these drugs within the ACC market, patient adoption of various therapies, and the sales figures associated with each drug.
• During the forecast period, drug uptake in ACC is expected to remain limited and gradual, reflecting the rarity of the disease and the constrained number of effective systemic options.
• Mitotane continues to form the backbone of treatment across both adjuvant and advanced settings, and is listed among the "Off-Patent, Off-Exclusivity Drugs without an Approved Generic" as outlined in the Orange Book.
• Pipeline candidate CY-101 is expected to enter the market as a novel immunomodulatory agent aiming to reshape anti-tumor immune responses while minimizing systemic toxicity, while DS-9051b is anticipated to follow a biomarker-driven adoption pathway, with early use potentially restricted to genetically or molecularly defined patient subsets.

Discover more about therapies set to grab major Adrenocortical Carcinoma market share @ Adrenocortical Carcinoma Treatment Landscape https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Adrenocortical Carcinoma Market Forecast: Presently, the market includes an approved product for ACC, Mitotane (LYSODREN), which remains the cornerstone adrenolytic agent used either alone or in combination with cytotoxic chemotherapy (the EDP-M regimen: etoposide, doxorubicin, cisplatin, and mitotane). The ACC market drivers include increasing diagnosis and awareness supported by improved imaging and hormonal testing, a growing pipeline of immunotherapy and targeted-therapy candidates such as CY-101, DS-9051b, and OR-449, and a high unmet medical need given the disease's aggressive nature, poor prognosis, and limited treatment options - all of which are expected to boost the market in the coming years.

Scope of the Adrenocortical Carcinoma Market Report:
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Adrenocortical Carcinoma Companies: Esteve, Daiichi Sankyo, Cytovation, Orphagen Pharmaceuticals, and others
• Key Adrenocortical Carcinoma Therapies: Mitotane (LYSODREN), DS9051b/DS-9051, CY-101/Getacatetide, OR-449, and others
• Adrenocortical Carcinoma Therapeutic Assessment: ACC current marketed and ACC emerging therapies
• Adrenocortical Carcinoma Market Dynamics: ACC market drivers and ACC market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, Conjoint Analysis, Market entry strategies
• Adrenocortical Carcinoma Unmet Needs, KOL's views, Analyst's views, Adrenocortical Carcinoma Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.